patient_id|note_date|note_text
1|2022-10-10|Patient tolerating medication without issues.
1|2022-10-24|No gastrointestinal adverse effects reported. Patient tolerating medication without issues.
2|2022-10-11|Started GLP-1 therapy for weight management.
3|2022-10-14|No prior diagnosis of diabetes noted.
3|2022-10-30|Reports intermittent gastrointestinal symptoms.
3|2022-11-01|Denies nausea, vomiting, or abdominal pain. Semaglutide initiated at prior visit.
4|2022-10-07|No prior diagnosis of diabetes noted.
4|2022-10-10|GLP-1 therapy discussed during visit.
4|2022-10-20|Patient tolerating medication without issues. History of type 2 diabetes mellitus.
5|2022-11-17|Follow-up visit after GLP-1 initiation.
6|2022-10-08|No prior diagnosis of diabetes noted.
6|2022-11-18|No gastrointestinal adverse effects reported.
7|2022-11-06|Reports mild nausea following injections. Semaglutide initiated at prior visit.
8|2022-10-13|Patient reports increased appetite and recent weight gain. No gastrointestinal adverse effects reported.
8|2022-10-19|No gastrointestinal adverse effects reported.
9|2022-11-07|Reports intermittent gastrointestinal symptoms. Denies nausea, vomiting, or abdominal pain.
9|2022-11-13|History of type 2 diabetes mellitus.
10|2022-10-02|Denies nausea, vomiting, or abdominal pain.
11|2022-11-09|Semaglutide initiated at prior visit.
12|2022-10-29|Semaglutide initiated at prior visit. Patient tolerating medication without issues.
13|2022-11-07|Reports intermittent gastrointestinal symptoms.
14|2022-10-13|Started GLP-1 therapy for weight management.
14|2022-11-04|HbA1c previously elevated per chart review.
15|2022-11-13|HbA1c previously elevated per chart review.
16|2022-10-05|Reports mild nausea following injections. Denies nausea, vomiting, or abdominal pain.
16|2022-10-24|Reports intermittent gastrointestinal symptoms. Patient reports increased appetite and recent weight gain.
16|2022-10-25|GLP-1 therapy discussed during visit.
17|2022-11-29|GLP-1 therapy discussed during visit. Lifestyle modification counseling provided.
18|2022-10-10|History of type 2 diabetes mellitus. GLP-1 therapy discussed during visit.
19|2022-11-12|No prior diagnosis of diabetes noted.
20|2022-10-02|Lifestyle modification counseling provided.
20|2022-11-18|HbA1c previously elevated per chart review.
20|2022-11-29|No gastrointestinal adverse effects reported. Started GLP-1 therapy for weight management.
21|2022-11-16|History of type 2 diabetes mellitus. Patient tolerating medication without issues.
21|2022-11-29|Patient reports increased appetite and recent weight gain. Reports intermittent gastrointestinal symptoms.
22|2022-10-10|Patient tolerating medication without issues. Lifestyle modification counseling provided.
22|2022-10-13|History of type 2 diabetes mellitus.
22|2022-10-29|Lifestyle modification counseling provided.
23|2022-11-01|Lifestyle modification counseling provided.
23|2022-11-14|Started GLP-1 therapy for weight management. Follow-up visit after GLP-1 initiation.
23|2022-11-23|No gastrointestinal adverse effects reported.
24|2022-10-16|Patient reports increased appetite and recent weight gain. GLP-1 therapy discussed during visit.
24|2022-10-28|Reports mild nausea following injections. History of type 2 diabetes mellitus.
25|2022-10-10|Reports mild nausea following injections.
25|2022-10-26|HbA1c previously elevated per chart review.
25|2022-11-02|Patient tolerating medication without issues. HbA1c previously elevated per chart review.
26|2022-11-20|Denies nausea, vomiting, or abdominal pain.
27|2022-10-02|Started GLP-1 therapy for weight management. History of type 2 diabetes mellitus.
27|2022-11-04|No prior diagnosis of diabetes noted. Patient reports increased appetite and recent weight gain.
28|2022-10-03|Discontinued GLP-1 due to GI intolerance.
28|2022-11-21|Reports intermittent gastrointestinal symptoms. Patient tolerating medication without issues.
29|2022-11-19|Patient tolerating medication without issues. Patient reports increased appetite and recent weight gain.
30|2022-10-04|History of type 2 diabetes mellitus.
30|2022-10-29|Reports mild nausea following injections.
30|2022-11-03|No prior diagnosis of diabetes noted. History of type 2 diabetes mellitus.
31|2022-11-03|Reports mild nausea following injections.
31|2022-11-20|No gastrointestinal adverse effects reported.
32|2022-10-11|Semaglutide initiated at prior visit.
32|2022-11-12|Patient reports increased appetite and recent weight gain. Follow-up visit after GLP-1 initiation.
32|2022-11-16|Lifestyle modification counseling provided.
33|2022-10-08|Patient reports increased appetite and recent weight gain.
33|2022-10-26|GLP-1 therapy discussed during visit.
33|2022-11-28|No prior diagnosis of diabetes noted. Semaglutide initiated at prior visit.
34|2022-10-04|GLP-1 therapy discussed during visit. History of type 2 diabetes mellitus.
34|2022-10-10|Started GLP-1 therapy for weight management. Reports mild nausea following injections.
34|2022-10-30|Denies nausea, vomiting, or abdominal pain.
35|2022-11-10|No gastrointestinal adverse effects reported. Started GLP-1 therapy for weight management.
36|2022-11-01|Lifestyle modification counseling provided. Patient reports increased appetite and recent weight gain.
36|2022-11-14|Semaglutide initiated at prior visit.
37|2022-10-01|Patient reports increased appetite and recent weight gain.
37|2022-11-21|HbA1c previously elevated per chart review. Discontinued GLP-1 due to GI intolerance.
37|2022-11-26|Denies nausea, vomiting, or abdominal pain.
38|2022-10-06|Lifestyle modification counseling provided.
39|2022-10-24|Follow-up visit after GLP-1 initiation. Patient tolerating medication without issues.
40|2022-10-05|No gastrointestinal adverse effects reported. Reports mild nausea following injections.
40|2022-10-21|Semaglutide initiated at prior visit.
41|2022-10-22|History of type 2 diabetes mellitus. Patient tolerating medication without issues.
41|2022-11-26|Started GLP-1 therapy for weight management. Discontinued GLP-1 due to GI intolerance.
42|2022-10-27|Patient reports increased appetite and recent weight gain.
42|2022-11-16|History of type 2 diabetes mellitus. Discontinued GLP-1 due to GI intolerance.
43|2022-10-05|Reports mild nausea following injections. History of type 2 diabetes mellitus.
43|2022-11-05|Discontinued GLP-1 due to GI intolerance.
44|2022-10-01|Denies nausea, vomiting, or abdominal pain.
44|2022-10-19|History of type 2 diabetes mellitus. No gastrointestinal adverse effects reported.
45|2022-10-30|Denies nausea, vomiting, or abdominal pain. History of type 2 diabetes mellitus.
45|2022-11-07|Reports mild nausea following injections.
45|2022-11-24|Denies nausea, vomiting, or abdominal pain. Discontinued GLP-1 due to GI intolerance.
46|2022-10-19|HbA1c previously elevated per chart review. Reports intermittent gastrointestinal symptoms.
46|2022-11-15|No gastrointestinal adverse effects reported. HbA1c previously elevated per chart review.
47|2022-11-28|Semaglutide initiated at prior visit.
48|2022-10-21|Follow-up visit after GLP-1 initiation. Semaglutide initiated at prior visit.
48|2022-10-28|Reports intermittent gastrointestinal symptoms.
48|2022-10-30|Reports mild nausea following injections.
49|2022-10-22|Reports intermittent gastrointestinal symptoms.
49|2022-10-28|Patient reports increased appetite and recent weight gain.
50|2022-11-03|Reports mild nausea following injections.
50|2022-11-04|HbA1c previously elevated per chart review.
50|2022-11-15|Semaglutide initiated at prior visit. Patient tolerating medication without issues.
51|2022-10-15|HbA1c previously elevated per chart review. No gastrointestinal adverse effects reported.
51|2022-10-22|HbA1c previously elevated per chart review. History of type 2 diabetes mellitus.
51|2022-11-27|HbA1c previously elevated per chart review.
52|2022-11-13|Reports mild nausea following injections.
52|2022-11-19|Follow-up visit after GLP-1 initiation.
53|2022-10-25|Started GLP-1 therapy for weight management. Discontinued GLP-1 due to GI intolerance.
53|2022-11-24|Denies nausea, vomiting, or abdominal pain.
54|2022-11-13|Reports mild nausea following injections. Patient reports increased appetite and recent weight gain.
54|2022-11-19|No gastrointestinal adverse effects reported. Reports intermittent gastrointestinal symptoms.
55|2022-10-18|Discontinued GLP-1 due to GI intolerance. Follow-up visit after GLP-1 initiation.
56|2022-10-27|No prior diagnosis of diabetes noted. Lifestyle modification counseling provided.
56|2022-11-04|Patient reports increased appetite and recent weight gain.
56|2022-11-23|Follow-up visit after GLP-1 initiation. Reports mild nausea following injections.
57|2022-10-31|No prior diagnosis of diabetes noted.
58|2022-11-07|Follow-up visit after GLP-1 initiation.
59|2022-11-04|Reports intermittent gastrointestinal symptoms.
59|2022-11-17|Reports intermittent gastrointestinal symptoms. Discontinued GLP-1 due to GI intolerance.
60|2022-11-21|Patient reports increased appetite and recent weight gain.
61|2022-10-16|GLP-1 therapy discussed during visit.
61|2022-10-26|GLP-1 therapy discussed during visit. Patient tolerating medication without issues.
61|2022-11-12|Discontinued GLP-1 due to GI intolerance.
62|2022-10-23|Patient tolerating medication without issues. Semaglutide initiated at prior visit.
63|2022-10-05|Denies nausea, vomiting, or abdominal pain.
64|2022-10-04|Follow-up visit after GLP-1 initiation. GLP-1 therapy discussed during visit.
64|2022-10-07|Reports mild nausea following injections.
64|2022-10-27|Patient tolerating medication without issues.
65|2022-10-28|Lifestyle modification counseling provided.
66|2022-10-25|History of type 2 diabetes mellitus. HbA1c previously elevated per chart review.
66|2022-11-06|History of type 2 diabetes mellitus. Denies nausea, vomiting, or abdominal pain.
67|2022-11-20|Semaglutide initiated at prior visit. Denies nausea, vomiting, or abdominal pain.
68|2022-10-07|Reports mild nausea following injections. HbA1c previously elevated per chart review.
68|2022-10-10|GLP-1 therapy discussed during visit.
68|2022-11-23|Discontinued GLP-1 due to GI intolerance.
69|2022-10-11|Patient tolerating medication without issues.
69|2022-11-08|Lifestyle modification counseling provided.
69|2022-11-26|Denies nausea, vomiting, or abdominal pain.
70|2022-10-24|Reports intermittent gastrointestinal symptoms.
70|2022-11-15|GLP-1 therapy discussed during visit. HbA1c previously elevated per chart review.
71|2022-10-15|History of type 2 diabetes mellitus.
71|2022-11-13|Patient tolerating medication without issues.
72|2022-10-10|No gastrointestinal adverse effects reported. Denies nausea, vomiting, or abdominal pain.
72|2022-10-19|Started GLP-1 therapy for weight management.
72|2022-10-27|Patient tolerating medication without issues. Semaglutide initiated at prior visit.
73|2022-10-01|Discontinued GLP-1 due to GI intolerance. Reports mild nausea following injections.
73|2022-10-11|GLP-1 therapy discussed during visit. Denies nausea, vomiting, or abdominal pain.
73|2022-11-13|Patient tolerating medication without issues.
74|2022-10-07|No prior diagnosis of diabetes noted. HbA1c previously elevated per chart review.
74|2022-10-29|Reports mild nausea following injections.
74|2022-11-28|No gastrointestinal adverse effects reported.
75|2022-10-11|No gastrointestinal adverse effects reported. Discontinued GLP-1 due to GI intolerance.
75|2022-10-19|Semaglutide initiated at prior visit. Reports intermittent gastrointestinal symptoms.
75|2022-11-06|Reports mild nausea following injections.
76|2022-10-11|No gastrointestinal adverse effects reported. Follow-up visit after GLP-1 initiation.
76|2022-10-12|Started GLP-1 therapy for weight management.
77|2022-10-12|History of type 2 diabetes mellitus. HbA1c previously elevated per chart review.
77|2022-10-18|Follow-up visit after GLP-1 initiation. History of type 2 diabetes mellitus.
77|2022-10-28|HbA1c previously elevated per chart review. No prior diagnosis of diabetes noted.
78|2022-10-20|No prior diagnosis of diabetes noted.
78|2022-11-10|Discontinued GLP-1 due to GI intolerance.
78|2022-11-28|Denies nausea, vomiting, or abdominal pain. Discontinued GLP-1 due to GI intolerance.
79|2022-11-11|No gastrointestinal adverse effects reported. Follow-up visit after GLP-1 initiation.
80|2022-10-16|Patient reports increased appetite and recent weight gain.
80|2022-11-29|Denies nausea, vomiting, or abdominal pain. HbA1c previously elevated per chart review.
81|2022-11-14|Lifestyle modification counseling provided. Follow-up visit after GLP-1 initiation.
82|2022-10-16|Reports intermittent gastrointestinal symptoms.
83|2022-10-01|HbA1c previously elevated per chart review.
83|2022-10-27|Denies nausea, vomiting, or abdominal pain.
84|2022-11-08|History of type 2 diabetes mellitus. HbA1c previously elevated per chart review.
84|2022-11-16|Patient tolerating medication without issues.
85|2022-10-02|GLP-1 therapy discussed during visit. No gastrointestinal adverse effects reported.
86|2022-11-09|Reports mild nausea following injections.
87|2022-10-22|Semaglutide initiated at prior visit. No prior diagnosis of diabetes noted.
88|2022-11-15|No gastrointestinal adverse effects reported. Reports mild nausea following injections.
88|2022-11-22|Lifestyle modification counseling provided. Patient reports increased appetite and recent weight gain.
88|2022-11-28|GLP-1 therapy discussed during visit. Discontinued GLP-1 due to GI intolerance.
89|2022-10-19|Reports mild nausea following injections.
89|2022-11-02|Reports intermittent gastrointestinal symptoms.
90|2022-10-05|GLP-1 therapy discussed during visit. Lifestyle modification counseling provided.
90|2022-10-25|Patient tolerating medication without issues. Patient reports increased appetite and recent weight gain.
90|2022-11-04|Lifestyle modification counseling provided.
91|2022-10-14|Lifestyle modification counseling provided. Reports intermittent gastrointestinal symptoms.
91|2022-10-30|Started GLP-1 therapy for weight management. No gastrointestinal adverse effects reported.
91|2022-11-02|No gastrointestinal adverse effects reported.
92|2022-10-08|Patient tolerating medication without issues.
92|2022-10-16|No prior diagnosis of diabetes noted.
92|2022-11-27|Lifestyle modification counseling provided. Follow-up visit after GLP-1 initiation.
93|2022-11-04|Denies nausea, vomiting, or abdominal pain. Started GLP-1 therapy for weight management.
93|2022-11-23|Follow-up visit after GLP-1 initiation.
94|2022-11-01|Reports intermittent gastrointestinal symptoms. Follow-up visit after GLP-1 initiation.
94|2022-11-21|Lifestyle modification counseling provided. History of type 2 diabetes mellitus.
95|2022-10-22|Reports intermittent gastrointestinal symptoms.
96|2022-10-26|No prior diagnosis of diabetes noted.
96|2022-11-19|No prior diagnosis of diabetes noted. History of type 2 diabetes mellitus.
97|2022-11-15|Denies nausea, vomiting, or abdominal pain.
98|2022-10-26|No gastrointestinal adverse effects reported. Patient tolerating medication without issues.
99|2022-10-17|Reports mild nausea following injections.
99|2022-11-18|No prior diagnosis of diabetes noted. Lifestyle modification counseling provided.
99|2022-11-25|Reports mild nausea following injections. Follow-up visit after GLP-1 initiation.
100|2022-10-12|Reports mild nausea following injections.
100|2022-11-12|GLP-1 therapy discussed during visit. No prior diagnosis of diabetes noted.
100|2022-11-27|No prior diagnosis of diabetes noted.
101|2022-10-16|History of type 2 diabetes mellitus. Reports mild nausea following injections.
102|2022-11-13|Reports mild nausea following injections.
102|2022-11-17|Denies nausea, vomiting, or abdominal pain.
102|2022-11-22|Follow-up visit after GLP-1 initiation. Started GLP-1 therapy for weight management.
103|2022-10-15|Started GLP-1 therapy for weight management.
103|2022-10-17|Denies nausea, vomiting, or abdominal pain.
103|2022-11-04|No prior diagnosis of diabetes noted.
104|2022-11-07|No gastrointestinal adverse effects reported. Reports intermittent gastrointestinal symptoms.
105|2022-10-24|HbA1c previously elevated per chart review. Patient reports increased appetite and recent weight gain.
105|2022-11-11|Denies nausea, vomiting, or abdominal pain. GLP-1 therapy discussed during visit.
105|2022-11-15|Semaglutide initiated at prior visit. HbA1c previously elevated per chart review.
106|2022-10-22|Started GLP-1 therapy for weight management. Lifestyle modification counseling provided.
107|2022-10-12|GLP-1 therapy discussed during visit.
107|2022-11-07|Semaglutide initiated at prior visit. Discontinued GLP-1 due to GI intolerance.
107|2022-11-16|No prior diagnosis of diabetes noted. History of type 2 diabetes mellitus.
108|2022-10-06|Reports mild nausea following injections.
108|2022-10-11|HbA1c previously elevated per chart review.
109|2022-11-28|Discontinued GLP-1 due to GI intolerance.
110|2022-10-30|Started GLP-1 therapy for weight management.
110|2022-11-15|Patient tolerating medication without issues. Discontinued GLP-1 due to GI intolerance.
111|2022-11-13|Started GLP-1 therapy for weight management.
111|2022-11-26|HbA1c previously elevated per chart review. GLP-1 therapy discussed during visit.
112|2022-10-08|Follow-up visit after GLP-1 initiation.
112|2022-10-13|Reports intermittent gastrointestinal symptoms. HbA1c previously elevated per chart review.
113|2022-10-20|Denies nausea, vomiting, or abdominal pain.
114|2022-10-25|No prior diagnosis of diabetes noted. Follow-up visit after GLP-1 initiation.
114|2022-11-24|Reports intermittent gastrointestinal symptoms.
115|2022-10-25|Denies nausea, vomiting, or abdominal pain. Patient reports increased appetite and recent weight gain.
115|2022-11-01|History of type 2 diabetes mellitus. Patient tolerating medication without issues.
115|2022-11-02|GLP-1 therapy discussed during visit. Patient reports increased appetite and recent weight gain.
116|2022-10-02|Started GLP-1 therapy for weight management.
116|2022-11-25|HbA1c previously elevated per chart review. Denies nausea, vomiting, or abdominal pain.
117|2022-11-01|Follow-up visit after GLP-1 initiation.
118|2022-10-31|Follow-up visit after GLP-1 initiation.
119|2022-10-07|Reports intermittent gastrointestinal symptoms. No gastrointestinal adverse effects reported.
119|2022-11-07|Reports intermittent gastrointestinal symptoms.
120|2022-10-09|No gastrointestinal adverse effects reported. Patient tolerating medication without issues.
120|2022-10-17|Patient reports increased appetite and recent weight gain.
121|2022-10-08|Lifestyle modification counseling provided.
122|2022-10-03|Denies nausea, vomiting, or abdominal pain.
122|2022-11-13|No prior diagnosis of diabetes noted.
123|2022-11-14|Denies nausea, vomiting, or abdominal pain. No prior diagnosis of diabetes noted.
123|2022-11-16|Follow-up visit after GLP-1 initiation.
123|2022-11-23|No prior diagnosis of diabetes noted.
124|2022-11-21|History of type 2 diabetes mellitus. Denies nausea, vomiting, or abdominal pain.
125|2022-10-06|Follow-up visit after GLP-1 initiation.
125|2022-11-26|No gastrointestinal adverse effects reported.
126|2022-10-01|Denies nausea, vomiting, or abdominal pain.
126|2022-10-26|Patient reports increased appetite and recent weight gain. History of type 2 diabetes mellitus.
127|2022-11-02|Discontinued GLP-1 due to GI intolerance.
127|2022-11-10|No prior diagnosis of diabetes noted. Patient reports increased appetite and recent weight gain.
128|2022-10-02|No prior diagnosis of diabetes noted. HbA1c previously elevated per chart review.
128|2022-11-06|Reports intermittent gastrointestinal symptoms. HbA1c previously elevated per chart review.
128|2022-11-20|Patient tolerating medication without issues. No prior diagnosis of diabetes noted.
129|2022-10-14|Started GLP-1 therapy for weight management. Lifestyle modification counseling provided.
129|2022-10-17|Denies nausea, vomiting, or abdominal pain. Reports mild nausea following injections.
129|2022-11-17|GLP-1 therapy discussed during visit.
130|2022-10-04|Follow-up visit after GLP-1 initiation.
130|2022-10-06|Reports mild nausea following injections. History of type 2 diabetes mellitus.
130|2022-10-17|Reports mild nausea following injections. Patient reports increased appetite and recent weight gain.
131|2022-10-19|Reports mild nausea following injections. No prior diagnosis of diabetes noted.
132|2022-10-02|No gastrointestinal adverse effects reported.
133|2022-10-05|Lifestyle modification counseling provided.
133|2022-10-08|Follow-up visit after GLP-1 initiation. GLP-1 therapy discussed during visit.
134|2022-10-15|GLP-1 therapy discussed during visit.
135|2022-10-12|No gastrointestinal adverse effects reported. Lifestyle modification counseling provided.
135|2022-11-04|Semaglutide initiated at prior visit.
136|2022-10-07|No gastrointestinal adverse effects reported.
136|2022-11-08|No gastrointestinal adverse effects reported.
137|2022-10-29|No gastrointestinal adverse effects reported.
137|2022-11-02|Started GLP-1 therapy for weight management. HbA1c previously elevated per chart review.
137|2022-11-18|GLP-1 therapy discussed during visit.
138|2022-10-08|Lifestyle modification counseling provided.
138|2022-11-01|No gastrointestinal adverse effects reported. Started GLP-1 therapy for weight management.
138|2022-11-24|Discontinued GLP-1 due to GI intolerance.
139|2022-10-04|No prior diagnosis of diabetes noted. GLP-1 therapy discussed during visit.
139|2022-11-11|Started GLP-1 therapy for weight management. Denies nausea, vomiting, or abdominal pain.
140|2022-10-14|Discontinued GLP-1 due to GI intolerance. Reports mild nausea following injections.
140|2022-10-17|Discontinued GLP-1 due to GI intolerance. Reports intermittent gastrointestinal symptoms.
140|2022-11-26|Reports intermittent gastrointestinal symptoms.
141|2022-10-11|Patient reports increased appetite and recent weight gain.
141|2022-10-23|Reports mild nausea following injections. Follow-up visit after GLP-1 initiation.
141|2022-10-30|Started GLP-1 therapy for weight management.
142|2022-10-21|Patient tolerating medication without issues.
143|2022-10-11|Discontinued GLP-1 due to GI intolerance.
143|2022-11-07|Denies nausea, vomiting, or abdominal pain.
144|2022-10-01|Denies nausea, vomiting, or abdominal pain. Follow-up visit after GLP-1 initiation.
144|2022-11-15|Patient tolerating medication without issues.
144|2022-11-25|History of type 2 diabetes mellitus.
145|2022-11-19|Reports intermittent gastrointestinal symptoms. Denies nausea, vomiting, or abdominal pain.
146|2022-10-23|HbA1c previously elevated per chart review.
147|2022-10-26|HbA1c previously elevated per chart review. Lifestyle modification counseling provided.
147|2022-11-10|No prior diagnosis of diabetes noted.
148|2022-11-09|Reports mild nausea following injections. HbA1c previously elevated per chart review.
148|2022-11-28|GLP-1 therapy discussed during visit. No gastrointestinal adverse effects reported.
149|2022-10-04|Lifestyle modification counseling provided.
150|2022-10-14|Discontinued GLP-1 due to GI intolerance.
150|2022-11-11|No gastrointestinal adverse effects reported.
150|2022-11-26|Patient reports increased appetite and recent weight gain. Lifestyle modification counseling provided.
151|2022-10-06|Patient tolerating medication without issues.
151|2022-11-29|Reports mild nausea following injections.
152|2022-10-19|History of type 2 diabetes mellitus. Denies nausea, vomiting, or abdominal pain.
152|2022-11-06|Denies nausea, vomiting, or abdominal pain.
153|2022-10-15|Discontinued GLP-1 due to GI intolerance.
153|2022-10-30|Lifestyle modification counseling provided. Reports mild nausea following injections.
154|2022-10-06|Discontinued GLP-1 due to GI intolerance.
154|2022-10-13|No prior diagnosis of diabetes noted. Started GLP-1 therapy for weight management.
154|2022-11-20|Follow-up visit after GLP-1 initiation.
155|2022-11-14|No gastrointestinal adverse effects reported. No prior diagnosis of diabetes noted.
155|2022-11-16|Patient tolerating medication without issues.
155|2022-11-19|Denies nausea, vomiting, or abdominal pain.
156|2022-10-21|Denies nausea, vomiting, or abdominal pain.
157|2022-10-08|Discontinued GLP-1 due to GI intolerance. No prior diagnosis of diabetes noted.
157|2022-11-12|Started GLP-1 therapy for weight management.
158|2022-11-20|No prior diagnosis of diabetes noted. Semaglutide initiated at prior visit.
158|2022-11-24|No prior diagnosis of diabetes noted. History of type 2 diabetes mellitus.
159|2022-10-20|Started GLP-1 therapy for weight management. Follow-up visit after GLP-1 initiation.
159|2022-10-22|Lifestyle modification counseling provided. GLP-1 therapy discussed during visit.
160|2022-11-15|Patient tolerating medication without issues. HbA1c previously elevated per chart review.
161|2022-11-04|Follow-up visit after GLP-1 initiation.
162|2022-10-23|No prior diagnosis of diabetes noted. Semaglutide initiated at prior visit.
163|2022-10-07|Reports intermittent gastrointestinal symptoms. Denies nausea, vomiting, or abdominal pain.
163|2022-10-15|GLP-1 therapy discussed during visit.
163|2022-11-14|Follow-up visit after GLP-1 initiation. GLP-1 therapy discussed during visit.
164|2022-10-08|No gastrointestinal adverse effects reported.
164|2022-10-09|Follow-up visit after GLP-1 initiation. Started GLP-1 therapy for weight management.
164|2022-10-24|Lifestyle modification counseling provided. Denies nausea, vomiting, or abdominal pain.
165|2022-10-26|Reports mild nausea following injections. Reports intermittent gastrointestinal symptoms.
166|2022-10-06|History of type 2 diabetes mellitus. HbA1c previously elevated per chart review.
166|2022-10-27|Follow-up visit after GLP-1 initiation.
167|2022-10-05|Patient tolerating medication without issues.
167|2022-11-05|Reports mild nausea following injections. Patient tolerating medication without issues.
167|2022-11-19|GLP-1 therapy discussed during visit. Follow-up visit after GLP-1 initiation.
168|2022-10-31|No gastrointestinal adverse effects reported.
168|2022-11-15|Started GLP-1 therapy for weight management. Lifestyle modification counseling provided.
168|2022-11-25|HbA1c previously elevated per chart review.
169|2022-10-10|Discontinued GLP-1 due to GI intolerance. HbA1c previously elevated per chart review.
169|2022-10-29|Denies nausea, vomiting, or abdominal pain. GLP-1 therapy discussed during visit.
169|2022-11-13|Discontinued GLP-1 due to GI intolerance. Denies nausea, vomiting, or abdominal pain.
170|2022-10-29|Denies nausea, vomiting, or abdominal pain. No prior diagnosis of diabetes noted.
171|2022-10-27|Semaglutide initiated at prior visit.
171|2022-11-29|Patient tolerating medication without issues. Denies nausea, vomiting, or abdominal pain.
172|2022-10-01|No gastrointestinal adverse effects reported.
172|2022-11-28|GLP-1 therapy discussed during visit. No prior diagnosis of diabetes noted.
173|2022-10-21|Started GLP-1 therapy for weight management.
174|2022-10-16|History of type 2 diabetes mellitus. GLP-1 therapy discussed during visit.
174|2022-10-29|No gastrointestinal adverse effects reported.
174|2022-11-23|Semaglutide initiated at prior visit. Reports intermittent gastrointestinal symptoms.
175|2022-10-17|Reports intermittent gastrointestinal symptoms.
175|2022-11-03|Discontinued GLP-1 due to GI intolerance. No gastrointestinal adverse effects reported.
176|2022-10-21|Patient reports increased appetite and recent weight gain. Reports mild nausea following injections.
176|2022-11-04|Started GLP-1 therapy for weight management.
177|2022-10-12|History of type 2 diabetes mellitus.
177|2022-11-17|Semaglutide initiated at prior visit.
178|2022-10-04|Semaglutide initiated at prior visit. No gastrointestinal adverse effects reported.
178|2022-10-14|HbA1c previously elevated per chart review.
178|2022-10-15|Patient tolerating medication without issues.
179|2022-10-27|Patient reports increased appetite and recent weight gain. Lifestyle modification counseling provided.
180|2022-10-09|Follow-up visit after GLP-1 initiation.
180|2022-11-10|Reports intermittent gastrointestinal symptoms. Lifestyle modification counseling provided.
181|2022-10-02|No gastrointestinal adverse effects reported. History of type 2 diabetes mellitus.
181|2022-10-25|Reports intermittent gastrointestinal symptoms. Denies nausea, vomiting, or abdominal pain.
182|2022-10-21|Reports intermittent gastrointestinal symptoms. Patient reports increased appetite and recent weight gain.
182|2022-10-22|HbA1c previously elevated per chart review.
182|2022-11-08|Reports mild nausea following injections. Lifestyle modification counseling provided.
183|2022-10-01|Follow-up visit after GLP-1 initiation. Reports intermittent gastrointestinal symptoms.
184|2022-10-06|History of type 2 diabetes mellitus.
184|2022-10-17|Reports intermittent gastrointestinal symptoms.
184|2022-10-19|Reports intermittent gastrointestinal symptoms. HbA1c previously elevated per chart review.
185|2022-10-12|HbA1c previously elevated per chart review. Patient tolerating medication without issues.
185|2022-11-04|Reports intermittent gastrointestinal symptoms. No gastrointestinal adverse effects reported.
185|2022-11-29|Reports mild nausea following injections.
186|2022-10-10|Reports intermittent gastrointestinal symptoms.
186|2022-11-14|Reports intermittent gastrointestinal symptoms. Denies nausea, vomiting, or abdominal pain.
186|2022-11-17|Lifestyle modification counseling provided. No prior diagnosis of diabetes noted.
187|2022-10-23|History of type 2 diabetes mellitus. No prior diagnosis of diabetes noted.
187|2022-11-08|Lifestyle modification counseling provided. Denies nausea, vomiting, or abdominal pain.
187|2022-11-22|No prior diagnosis of diabetes noted. Patient reports increased appetite and recent weight gain.
188|2022-10-28|No gastrointestinal adverse effects reported. Follow-up visit after GLP-1 initiation.
188|2022-11-17|Lifestyle modification counseling provided. Discontinued GLP-1 due to GI intolerance.
189|2022-11-05|Semaglutide initiated at prior visit. No gastrointestinal adverse effects reported.
190|2022-11-06|Discontinued GLP-1 due to GI intolerance.
191|2022-10-28|HbA1c previously elevated per chart review.
191|2022-11-03|GLP-1 therapy discussed during visit.
191|2022-11-18|HbA1c previously elevated per chart review. History of type 2 diabetes mellitus.
192|2022-10-25|Reports intermittent gastrointestinal symptoms.
192|2022-11-04|Lifestyle modification counseling provided.
192|2022-11-19|Patient tolerating medication without issues. History of type 2 diabetes mellitus.
193|2022-11-02|GLP-1 therapy discussed during visit.
193|2022-11-29|No gastrointestinal adverse effects reported. Follow-up visit after GLP-1 initiation.
194|2022-10-05|Reports mild nausea following injections. No prior diagnosis of diabetes noted.
194|2022-11-19|GLP-1 therapy discussed during visit. No gastrointestinal adverse effects reported.
195|2022-10-22|Discontinued GLP-1 due to GI intolerance.
195|2022-11-22|Discontinued GLP-1 due to GI intolerance. Patient tolerating medication without issues.
196|2022-11-19|Semaglutide initiated at prior visit.
197|2022-10-31|HbA1c previously elevated per chart review. Started GLP-1 therapy for weight management.
198|2022-10-12|Semaglutide initiated at prior visit. Discontinued GLP-1 due to GI intolerance.
198|2022-10-17|Denies nausea, vomiting, or abdominal pain. No gastrointestinal adverse effects reported.
199|2022-11-25|No gastrointestinal adverse effects reported.
200|2022-10-11|Patient reports increased appetite and recent weight gain. Reports intermittent gastrointestinal symptoms.
200|2022-10-29|Semaglutide initiated at prior visit. Lifestyle modification counseling provided.
200|2022-11-07|Patient tolerating medication without issues.
201|2022-10-09|Reports mild nausea following injections. GLP-1 therapy discussed during visit.
201|2022-11-01|Patient tolerating medication without issues. Patient reports increased appetite and recent weight gain.
201|2022-11-02|Lifestyle modification counseling provided.
202|2022-10-19|Started GLP-1 therapy for weight management.
202|2022-10-21|Follow-up visit after GLP-1 initiation.
202|2022-11-23|GLP-1 therapy discussed during visit.
203|2022-10-29|Reports intermittent gastrointestinal symptoms. Patient reports increased appetite and recent weight gain.
203|2022-11-19|Reports mild nausea following injections. Discontinued GLP-1 due to GI intolerance.
203|2022-11-28|History of type 2 diabetes mellitus. No prior diagnosis of diabetes noted.
204|2022-10-28|GLP-1 therapy discussed during visit.
205|2022-10-05|Discontinued GLP-1 due to GI intolerance.
205|2022-10-07|No gastrointestinal adverse effects reported.
206|2022-10-05|No prior diagnosis of diabetes noted.
206|2022-10-08|Patient tolerating medication without issues.
206|2022-11-23|Reports mild nausea following injections.
207|2022-10-27|Reports mild nausea following injections. Discontinued GLP-1 due to GI intolerance.
208|2022-10-19|Follow-up visit after GLP-1 initiation. Reports mild nausea following injections.
209|2022-11-05|Patient reports increased appetite and recent weight gain. HbA1c previously elevated per chart review.
209|2022-11-24|History of type 2 diabetes mellitus. GLP-1 therapy discussed during visit.
210|2022-10-02|Patient tolerating medication without issues. No prior diagnosis of diabetes noted.
210|2022-11-17|Reports mild nausea following injections. Patient reports increased appetite and recent weight gain.
210|2022-11-19|GLP-1 therapy discussed during visit.
211|2022-10-12|Patient reports increased appetite and recent weight gain. History of type 2 diabetes mellitus.
211|2022-11-04|Reports mild nausea following injections.
211|2022-11-20|Semaglutide initiated at prior visit. Denies nausea, vomiting, or abdominal pain.
212|2022-11-06|Lifestyle modification counseling provided.
212|2022-11-11|Semaglutide initiated at prior visit. Reports mild nausea following injections.
213|2022-10-27|No gastrointestinal adverse effects reported. HbA1c previously elevated per chart review.
213|2022-10-28|No prior diagnosis of diabetes noted. HbA1c previously elevated per chart review.
213|2022-11-15|History of type 2 diabetes mellitus.
214|2022-10-30|Patient reports increased appetite and recent weight gain. Patient tolerating medication without issues.
214|2022-11-19|Follow-up visit after GLP-1 initiation. Reports intermittent gastrointestinal symptoms.
214|2022-11-24|Semaglutide initiated at prior visit. HbA1c previously elevated per chart review.
215|2022-10-25|No gastrointestinal adverse effects reported.
216|2022-10-09|Lifestyle modification counseling provided. Started GLP-1 therapy for weight management.
216|2022-11-13|Patient tolerating medication without issues. Denies nausea, vomiting, or abdominal pain.
217|2022-11-03|GLP-1 therapy discussed during visit. Patient reports increased appetite and recent weight gain.
217|2022-11-10|Follow-up visit after GLP-1 initiation. Denies nausea, vomiting, or abdominal pain.
217|2022-11-23|Reports intermittent gastrointestinal symptoms. Lifestyle modification counseling provided.
218|2022-10-10|Patient tolerating medication without issues. No gastrointestinal adverse effects reported.
218|2022-11-29|No gastrointestinal adverse effects reported.
219|2022-10-29|Lifestyle modification counseling provided. Patient tolerating medication without issues.
220|2022-10-27|No prior diagnosis of diabetes noted. Follow-up visit after GLP-1 initiation.
221|2022-10-19|Denies nausea, vomiting, or abdominal pain. Reports intermittent gastrointestinal symptoms.
221|2022-10-26|Denies nausea, vomiting, or abdominal pain. Reports mild nausea following injections.
222|2022-10-05|Reports mild nausea following injections.
222|2022-11-26|Discontinued GLP-1 due to GI intolerance. Started GLP-1 therapy for weight management.
223|2022-10-01|Lifestyle modification counseling provided.
223|2022-11-15|No prior diagnosis of diabetes noted. History of type 2 diabetes mellitus.
224|2022-10-16|HbA1c previously elevated per chart review.
225|2022-11-14|Patient reports increased appetite and recent weight gain.
225|2022-11-17|Discontinued GLP-1 due to GI intolerance.
226|2022-11-26|Patient reports increased appetite and recent weight gain.
227|2022-10-10|No gastrointestinal adverse effects reported. History of type 2 diabetes mellitus.
227|2022-10-17|HbA1c previously elevated per chart review.
227|2022-11-09|No prior diagnosis of diabetes noted.
228|2022-10-26|Reports intermittent gastrointestinal symptoms.
228|2022-11-07|HbA1c previously elevated per chart review.
228|2022-11-28|Follow-up visit after GLP-1 initiation. No gastrointestinal adverse effects reported.
229|2022-11-23|History of type 2 diabetes mellitus. Started GLP-1 therapy for weight management.
230|2022-10-01|Lifestyle modification counseling provided. Semaglutide initiated at prior visit.
231|2022-11-05|Patient reports increased appetite and recent weight gain.
231|2022-11-23|HbA1c previously elevated per chart review. Discontinued GLP-1 due to GI intolerance.
231|2022-11-27|Patient tolerating medication without issues. Reports intermittent gastrointestinal symptoms.
232|2022-10-25|Discontinued GLP-1 due to GI intolerance. Started GLP-1 therapy for weight management.
232|2022-10-27|Denies nausea, vomiting, or abdominal pain. HbA1c previously elevated per chart review.
233|2022-10-07|Patient tolerating medication without issues. HbA1c previously elevated per chart review.
233|2022-11-18|Reports intermittent gastrointestinal symptoms. GLP-1 therapy discussed during visit.
234|2022-10-28|Patient reports increased appetite and recent weight gain.
234|2022-11-18|Denies nausea, vomiting, or abdominal pain. Semaglutide initiated at prior visit.
235|2022-10-04|Semaglutide initiated at prior visit.
236|2022-10-30|Denies nausea, vomiting, or abdominal pain. No prior diagnosis of diabetes noted.
236|2022-11-03|Patient tolerating medication without issues. No prior diagnosis of diabetes noted.
237|2022-10-28|Reports intermittent gastrointestinal symptoms.
238|2022-10-13|Semaglutide initiated at prior visit. Started GLP-1 therapy for weight management.
239|2022-11-07|Lifestyle modification counseling provided.
240|2022-10-03|Started GLP-1 therapy for weight management. No prior diagnosis of diabetes noted.
240|2022-10-15|Discontinued GLP-1 due to GI intolerance. Denies nausea, vomiting, or abdominal pain.
240|2022-11-08|Reports mild nausea following injections. No gastrointestinal adverse effects reported.
241|2022-10-03|Patient tolerating medication without issues.
241|2022-10-10|Reports intermittent gastrointestinal symptoms.
242|2022-10-11|HbA1c previously elevated per chart review.
242|2022-10-25|History of type 2 diabetes mellitus.
242|2022-10-30|Follow-up visit after GLP-1 initiation.
243|2022-11-13|Semaglutide initiated at prior visit.
244|2022-10-06|History of type 2 diabetes mellitus. Patient tolerating medication without issues.
244|2022-11-04|Follow-up visit after GLP-1 initiation. Started GLP-1 therapy for weight management.
245|2022-10-10|Patient tolerating medication without issues. Denies nausea, vomiting, or abdominal pain.
245|2022-11-05|Lifestyle modification counseling provided. No gastrointestinal adverse effects reported.
245|2022-11-22|History of type 2 diabetes mellitus. Patient tolerating medication without issues.
246|2022-10-18|Denies nausea, vomiting, or abdominal pain.
246|2022-11-06|Patient tolerating medication without issues. History of type 2 diabetes mellitus.
246|2022-11-23|No prior diagnosis of diabetes noted.
247|2022-10-05|History of type 2 diabetes mellitus. Follow-up visit after GLP-1 initiation.
247|2022-10-24|Denies nausea, vomiting, or abdominal pain. Patient tolerating medication without issues.
247|2022-11-04|GLP-1 therapy discussed during visit. Lifestyle modification counseling provided.
248|2022-10-19|No prior diagnosis of diabetes noted.
248|2022-10-29|No prior diagnosis of diabetes noted.
249|2022-10-27|Reports intermittent gastrointestinal symptoms.
249|2022-11-04|Follow-up visit after GLP-1 initiation. HbA1c previously elevated per chart review.
249|2022-11-05|No gastrointestinal adverse effects reported.
250|2022-11-02|GLP-1 therapy discussed during visit. Discontinued GLP-1 due to GI intolerance.
250|2022-11-26|Patient tolerating medication without issues.
250|2022-11-28|Follow-up visit after GLP-1 initiation. Reports mild nausea following injections.
251|2022-11-22|No prior diagnosis of diabetes noted. Started GLP-1 therapy for weight management.
252|2022-11-14|Patient tolerating medication without issues.
253|2022-10-16|No prior diagnosis of diabetes noted.
253|2022-10-23|Denies nausea, vomiting, or abdominal pain.
253|2022-11-29|No gastrointestinal adverse effects reported. GLP-1 therapy discussed during visit.
254|2022-10-26|Follow-up visit after GLP-1 initiation. HbA1c previously elevated per chart review.
255|2022-10-02|No prior diagnosis of diabetes noted.
255|2022-11-11|Follow-up visit after GLP-1 initiation.
256|2022-10-15|Patient tolerating medication without issues. Denies nausea, vomiting, or abdominal pain.
256|2022-11-15|Discontinued GLP-1 due to GI intolerance.
257|2022-10-08|Reports mild nausea following injections.
257|2022-10-19|No prior diagnosis of diabetes noted.
257|2022-11-01|Started GLP-1 therapy for weight management. Reports intermittent gastrointestinal symptoms.
258|2022-10-05|Started GLP-1 therapy for weight management.
259|2022-10-02|Started GLP-1 therapy for weight management.
259|2022-10-12|No prior diagnosis of diabetes noted. Follow-up visit after GLP-1 initiation.
259|2022-11-19|Discontinued GLP-1 due to GI intolerance. GLP-1 therapy discussed during visit.
260|2022-10-05|Patient reports increased appetite and recent weight gain.
261|2022-10-02|Patient tolerating medication without issues.
261|2022-10-09|Denies nausea, vomiting, or abdominal pain.
261|2022-11-29|Semaglutide initiated at prior visit. Denies nausea, vomiting, or abdominal pain.
262|2022-10-05|GLP-1 therapy discussed during visit. No gastrointestinal adverse effects reported.
263|2022-10-14|Follow-up visit after GLP-1 initiation.
263|2022-11-05|GLP-1 therapy discussed during visit.
263|2022-11-09|No prior diagnosis of diabetes noted. Follow-up visit after GLP-1 initiation.
264|2022-11-04|Follow-up visit after GLP-1 initiation.
264|2022-11-16|Patient reports increased appetite and recent weight gain. Discontinued GLP-1 due to GI intolerance.
264|2022-11-24|No gastrointestinal adverse effects reported. Discontinued GLP-1 due to GI intolerance.
265|2022-10-04|Lifestyle modification counseling provided.
265|2022-10-31|Discontinued GLP-1 due to GI intolerance. Reports mild nausea following injections.
265|2022-11-20|HbA1c previously elevated per chart review.
266|2022-10-30|History of type 2 diabetes mellitus. Discontinued GLP-1 due to GI intolerance.
267|2022-10-11|Reports mild nausea following injections. HbA1c previously elevated per chart review.
268|2022-10-25|Discontinued GLP-1 due to GI intolerance.
268|2022-11-09|Lifestyle modification counseling provided.
269|2022-11-01|No prior diagnosis of diabetes noted. Discontinued GLP-1 due to GI intolerance.
269|2022-11-07|History of type 2 diabetes mellitus. Lifestyle modification counseling provided.
270|2022-10-11|Denies nausea, vomiting, or abdominal pain. Patient reports increased appetite and recent weight gain.
270|2022-10-17|HbA1c previously elevated per chart review. Follow-up visit after GLP-1 initiation.
271|2022-10-15|No prior diagnosis of diabetes noted.
271|2022-10-23|Semaglutide initiated at prior visit. Reports intermittent gastrointestinal symptoms.
271|2022-11-24|Patient tolerating medication without issues.
272|2022-10-15|Reports mild nausea following injections. History of type 2 diabetes mellitus.
272|2022-10-28|Reports mild nausea following injections.
272|2022-11-25|Reports intermittent gastrointestinal symptoms. No prior diagnosis of diabetes noted.
273|2022-11-22|Discontinued GLP-1 due to GI intolerance. Follow-up visit after GLP-1 initiation.
273|2022-11-23|Reports intermittent gastrointestinal symptoms. Denies nausea, vomiting, or abdominal pain.
274|2022-10-29|No gastrointestinal adverse effects reported. Reports intermittent gastrointestinal symptoms.
275|2022-10-01|History of type 2 diabetes mellitus.
275|2022-11-06|No gastrointestinal adverse effects reported. Lifestyle modification counseling provided.
276|2022-10-03|No prior diagnosis of diabetes noted. No gastrointestinal adverse effects reported.
276|2022-10-31|Reports intermittent gastrointestinal symptoms.
276|2022-11-23|Denies nausea, vomiting, or abdominal pain. HbA1c previously elevated per chart review.
277|2022-11-02|HbA1c previously elevated per chart review. Lifestyle modification counseling provided.
278|2022-10-14|Follow-up visit after GLP-1 initiation.
278|2022-10-19|No prior diagnosis of diabetes noted. No gastrointestinal adverse effects reported.
278|2022-11-20|No gastrointestinal adverse effects reported.
279|2022-10-06|Started GLP-1 therapy for weight management. Denies nausea, vomiting, or abdominal pain.
279|2022-10-24|Patient reports increased appetite and recent weight gain.
279|2022-10-28|GLP-1 therapy discussed during visit. Patient reports increased appetite and recent weight gain.
280|2022-10-09|GLP-1 therapy discussed during visit. No gastrointestinal adverse effects reported.
280|2022-10-16|Semaglutide initiated at prior visit. Follow-up visit after GLP-1 initiation.
281|2022-10-07|Reports mild nausea following injections. Patient reports increased appetite and recent weight gain.
281|2022-10-23|Reports mild nausea following injections. Patient tolerating medication without issues.
282|2022-10-10|Reports mild nausea following injections.
283|2022-10-07|Patient reports increased appetite and recent weight gain. Denies nausea, vomiting, or abdominal pain.
283|2022-10-08|GLP-1 therapy discussed during visit. Started GLP-1 therapy for weight management.
283|2022-10-18|Reports mild nausea following injections. History of type 2 diabetes mellitus.
284|2022-10-07|Reports intermittent gastrointestinal symptoms. Started GLP-1 therapy for weight management.
284|2022-11-01|History of type 2 diabetes mellitus. Started GLP-1 therapy for weight management.
284|2022-11-26|Discontinued GLP-1 due to GI intolerance.
285|2022-10-15|Semaglutide initiated at prior visit.
286|2022-10-01|Denies nausea, vomiting, or abdominal pain. Follow-up visit after GLP-1 initiation.
287|2022-10-20|HbA1c previously elevated per chart review. Lifestyle modification counseling provided.
287|2022-11-17|Reports intermittent gastrointestinal symptoms.
288|2022-10-28|Semaglutide initiated at prior visit.
288|2022-11-24|Follow-up visit after GLP-1 initiation. Patient tolerating medication without issues.
289|2022-11-05|Follow-up visit after GLP-1 initiation. Patient reports increased appetite and recent weight gain.
289|2022-11-26|History of type 2 diabetes mellitus.
290|2022-10-10|Started GLP-1 therapy for weight management.
290|2022-11-08|Follow-up visit after GLP-1 initiation. Patient tolerating medication without issues.
290|2022-11-10|Denies nausea, vomiting, or abdominal pain.
291|2022-10-24|No gastrointestinal adverse effects reported.
291|2022-10-26|Follow-up visit after GLP-1 initiation.
291|2022-10-28|Denies nausea, vomiting, or abdominal pain. Follow-up visit after GLP-1 initiation.
292|2022-11-19|GLP-1 therapy discussed during visit.
292|2022-11-25|Patient reports increased appetite and recent weight gain.
293|2022-11-09|No gastrointestinal adverse effects reported. Patient tolerating medication without issues.
294|2022-10-26|Lifestyle modification counseling provided.
295|2022-11-22|Reports mild nausea following injections. Denies nausea, vomiting, or abdominal pain.
296|2022-11-15|No gastrointestinal adverse effects reported. Lifestyle modification counseling provided.
297|2022-10-30|Started GLP-1 therapy for weight management.
298|2022-10-09|Lifestyle modification counseling provided.
298|2022-10-27|Patient tolerating medication without issues.
299|2022-10-02|Denies nausea, vomiting, or abdominal pain.
299|2022-11-18|History of type 2 diabetes mellitus.
300|2022-10-12|Discontinued GLP-1 due to GI intolerance.
300|2022-10-15|History of type 2 diabetes mellitus.
301|2022-10-12|No prior diagnosis of diabetes noted. Reports mild nausea following injections.
301|2022-11-20|Lifestyle modification counseling provided.
302|2022-10-14|Started GLP-1 therapy for weight management.
302|2022-11-05|Reports mild nausea following injections.
302|2022-11-13|Semaglutide initiated at prior visit. History of type 2 diabetes mellitus.
303|2022-10-01|Follow-up visit after GLP-1 initiation.
303|2022-11-03|HbA1c previously elevated per chart review. GLP-1 therapy discussed during visit.
303|2022-11-08|HbA1c previously elevated per chart review.
304|2022-10-10|History of type 2 diabetes mellitus.
305|2022-11-12|Denies nausea, vomiting, or abdominal pain. Patient tolerating medication without issues.
306|2022-10-08|Semaglutide initiated at prior visit. Discontinued GLP-1 due to GI intolerance.
307|2022-11-02|Follow-up visit after GLP-1 initiation.
308|2022-10-01|Semaglutide initiated at prior visit. Denies nausea, vomiting, or abdominal pain.
309|2022-10-14|GLP-1 therapy discussed during visit. Patient tolerating medication without issues.
309|2022-10-22|Started GLP-1 therapy for weight management.
310|2022-11-04|Follow-up visit after GLP-1 initiation. GLP-1 therapy discussed during visit.
310|2022-11-05|Patient tolerating medication without issues.
310|2022-11-24|Denies nausea, vomiting, or abdominal pain. Started GLP-1 therapy for weight management.
311|2022-10-31|History of type 2 diabetes mellitus. Reports mild nausea following injections.
312|2022-11-26|HbA1c previously elevated per chart review. No prior diagnosis of diabetes noted.
313|2022-10-13|No gastrointestinal adverse effects reported.
313|2022-11-18|Reports mild nausea following injections.
313|2022-11-28|Started GLP-1 therapy for weight management.
314|2022-10-17|Semaglutide initiated at prior visit. GLP-1 therapy discussed during visit.
314|2022-11-11|Patient reports increased appetite and recent weight gain.
314|2022-11-13|GLP-1 therapy discussed during visit. History of type 2 diabetes mellitus.
315|2022-10-12|Patient reports increased appetite and recent weight gain. Reports intermittent gastrointestinal symptoms.
315|2022-11-26|Denies nausea, vomiting, or abdominal pain.
316|2022-11-16|Reports intermittent gastrointestinal symptoms.
317|2022-11-07|Semaglutide initiated at prior visit.
317|2022-11-24|HbA1c previously elevated per chart review.
318|2022-10-25|GLP-1 therapy discussed during visit. Started GLP-1 therapy for weight management.
318|2022-10-26|Patient tolerating medication without issues.
319|2022-11-04|Reports mild nausea following injections.
320|2022-10-15|Patient reports increased appetite and recent weight gain. Patient tolerating medication without issues.
320|2022-10-28|Reports intermittent gastrointestinal symptoms. Discontinued GLP-1 due to GI intolerance.
320|2022-11-07|No gastrointestinal adverse effects reported.
